Evaluation of log-rank tests for infrequent observations from a multi-state process, with application to HPV vaccine efficacy

Statistics in Medicine

Volumn 23, Issue 23, 2004, Pages 3681-3696

  Kang, Minhee ^a   Lagakos, Stephen W ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

HPV; Log rank test; Multi state process; Vaccine efficacy

Indexed keywords

PLACEBO; VIRUS VACCINE;

ANALYTICAL ERROR; ARTICLE; CANCER PREVENTION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; GENITAL TRACT INFECTION; HUMAN; PERIODIC MEDICAL EXAMINATION; PERSISTENT VIRUS INFECTION; PRECANCER; PREVALENCE; RELIABILITY; SEXUALLY TRANSMITTED DISEASE; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYMPTOMATOLOGY; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CANCER;

BIOMETRY; CLINICAL TRIALS; ENDPOINT DETERMINATION; FEMALE; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VIRAL VACCINES;

EID: 9244221586     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1916     Document Type: Article

References (16)

1. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. The New England Journal of Medicine 1998; 338:423-428.
2. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, Rozendaal L, Remmink AJ, Risse EKJ, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJLM. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. The Lancet 1999; 354:20-25.
3. Moscicki A-B, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E, Palefsky J. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. The Journal of Pediatrics 1998; 132:277-284.
4. Liaw K-L, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. Journal of the National Cancer Institute 1999; 91:954-960.
5. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of the National Cancer Institute 2000; 92: 464-474.
6. Koutsky L, Ault K, Wheeler C, Brown D, Barr E, Alvarez F, Chiacchierini L, Jansen K. A controlled trial of a human papillomavirus type 16 vaccine. The New England Journal of Medicine 2002; 347 1645-1651.
7. Duffy SW, Rohan TE, McLaughlin JR. Design and analysis considerations in a cohort study involving repeated measurement of both exposure and outcome: the association between genital papillomavirus infection and risk of cervical intraepithelial neoplasia. Statistics in Medicine 1994; 13:379-390.
8. Fleming TR, Harrigton DP. Counting Processes and Survival Analysis. Wiley: New York, 1991.
9. Cox DR, Miller HD. The Theory of Stochastic Processes. Chapman & Hall: London, 1977.
10. Satten GA, Longini IM. Markov chains with measurement error: estimating the 'true' course of a marker of the progression of the human immunodefiency virus disease. Applied Statistics 1996; 45 275-295.
11. Rosychuk RJ, Thompson ME. A semi-Markov model for binary longitudinal responses subject to misclassification. The Canadian Journal of Statistics 2001; 29:395-404.
12. Bureau A, Shiboski S, Hughes JP. Applications of continuous time hidden Markov models to the study of misclassified disease outcomes. Statistics in Medicine 2003; 22:441-462.
13. Mayrand M-H, Coutlee F, Hankins C, Lapointe N, Forest P, De Ladurantaye M. The Canadian Women's HIV Study Group, Roger M. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. Journal of Clinical Microbiology 2000; 38 3388-3393.
14. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981; 68 316-319.
15. Wallenstein S, Wittes W. The power of the Mantel-Haenszel test for grouped failure time data. Biometrics 1993; 49 1077-1087.
16. Kang M, Lagakos SW. Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Statistical Methods in Medical Research 2004; 13:139-155.